Colorectal Cancers

The value of MRD assessment in oligometastic colorectal cancer

John Strickler, MD; Tanios S. Bekaii-Saab, MD
Key updates for MRD testing in patients with colorectal cancer

John Strickler, MD
A Post ASCO Update: Metastatic colorectal cancer: Navigating Options

Tanios S. Bekaii-Saab, MD
Colorectal cancer updates from ASCO 2026: Impact of ctDNA and MRD testing on guiding adjuvant chemotherapy and treatment response monitoring

John Strickler, MD; Tanios S. Bekaii-Saab, MD
What is the optimal approach to targeting BRAF V600E, HER2 overexpression, and KRAS G12C in patients with metastatic CRC?

John Strickler, MD
MRD for Colorectal Cancer in 2026: Incorporating the Latest Data Into Our Clinical Care

John Strickler, MD
Advances in the Management of Colorectal Cancer: Recent Evidence and Emerging Treatment Paradigms

John Strickler, MD
ctDNA-Guided Surveillance in Non-Operative Rectal Cancer

Colleen Ashley Donahue, MD
The Role of ctDNA-MRD Assessment in the Management of Colon Cancer

John Strickler, MD
Emerging Treatment Landscape for BRAF V600E Mutated Colon Cancer

John Strickler, MD
MRD and NGS Testing for Stage I-III Colorectal Cancer: Practice Changing Data in 2025

John Strickler, MD
MRD Testing for Colon Cancer: Do’s and Don’ts with a Positive Result

John Strickler, MD